NCT01929655View on ClinicalTrials.gov

Japanese BAY88-8223 Monotherapy Phase II Study

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 16, 2017

Study Completion Date

May 16, 2017

Conditions
Prostatic Neoplasms
Interventions
DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration

Trial Locations (16)

277-8577

Kashiwa

003-0804

Sapporo

060-8543

Sapporo

920-8641

Kanazawa

236-0004

Yokohama

980-8574

Sendai

589-8511

Sayama

431-3192

Hamamatsu

113-8431

Bunkyo-ku

113-8603

Bunkyo-ku

135-8550

Koto-ku

160-8582

Shinjuku-ku

260-8717

Chiba

812-8582

Fukuoka

860-0008

Kumamoto

700-8558

Okayama

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01929655 - Japanese BAY88-8223 Monotherapy Phase II Study | Biotech Hunter | Biotech Hunter